AIDS With Tuberculosis Clinical Trial
Official title:
Evaluation of the Pharmacokinetics of Antituberculosis Drugs and Tuberculosis Treatment Outcomes in HIV-tuberculosis Co-infected Ugandan Adults
Tuberculosis (TB) is a leading cause of death in HIV-infected individuals. There are insufficient data correlating concentrations of anti-TB drugs with treatment response. We hypothesize that sub-therapeutic concentrations of anti-TB drugs are associated with inadequate TB treatment response to Mycobacterium tuberculosis.
During the study periodic monitoring will be conducted to ensure that the protocol and Good
Clinical Practices (GCPs) are being followed.The monitors may review source documents to
confirm that the data recorded on CRFs is accurate. The study site may be subject to review
by the Institutional Review Board (IRB) and/or appropriate regulatory authorities.
A CRF will be completed for each included subject and will be signed by the investigator or
by an authorized staff member to attest that the data is true. Any corrections to entries
made in the CRFs, source documents must be dated, initialed and explained (if necessary) and
should not obscure the original entry. Qualit assurance will as also be performed regularly
on the CRFs.
The primary end point will be analyzed using Time to event (cure, death, relapse
etc)analysis and failure rates and hazard ratios will be calculated accordig to categorical
drug concentrations with proposed cutt offs.
Secondary end points will be analysed using time to event for occurence of toxicities which
will also be corelated to the drug concentrations.
;
Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05510973 -
Evaluation of Advanced HIV Disease Differentiated Care Model in Malawi
|
N/A |